Ren M et al. demonstrated that pharmacological inhibition of FGFR1 kinase activity with ponatinib may be effective for the treatment of lung cancer patients whose tumors overexpress FGFR1 [40]. This evidence concerns the gene FGFR1 and lung cancer.